Literature DB >> 17395973

Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre.

Brian Hung-Hin Lang1, Chung-Yau Lo, Wai-Fan Chan, King-Yin Lam, Koon-Yat Wan.   

Abstract

A number of risk-group stratification or staging systems have been found useful at stratifying patients with differentiated thyroid carcinoma into risk groups. Those identified as high risk could be subjected to more aggressive treatment, while those at low risk could be spared of such treatment. However, the best stratification system in patients with follicular thyroid carcinoma (FTC) remains unclear. Through a comprehensive MEDLINE search from 1965 to 2005, a total of 18 different staging systems were identified in the literature and 14 of them were applicable to 171 patients, with FTC managed at our institution from 1961 to 2001. Cancer-specific survivals (CSS) were calculated by Kaplan-Meier method and were compared by log-rank test. Using Cox proportional hazards analysis, the relative importance of each staging system in determining CSS was calculated by the proportion of variation in survival time explained (PVE). CSS were predicted by 13 out of the 14 staging systems significantly (P < 0.001). The three highest ranked staging systems by PVE were the new American Joint Committee on Cancer/Union Internationale Centre le Cancer 6th edition, tumour, node, metastases (TNM; 22.4), followed by the Clinical Class (21.2) and the metastases, age, completeness of resection, invasion, size (MACIS; 20.4). In conclusion, 13 out of the 14 presently available staging systems predicted CSS significantly in FTC. When predictability was measured by PVE, the TNM system was found to have the best predictability and thus, should be the stratification system of choice for FTC in the future.

Entities:  

Mesh:

Year:  2007        PMID: 17395973     DOI: 10.1677/erc.1.01284

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  15 in total

1.  Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database.

Authors:  Ryan K Orosco; Timon Hussain; Kevin T Brumund; Deborah K Oh; David C Chang; Michael Bouvet
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

2.  Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.

Authors:  Daniel Mankarios; Peter Baade; Pip Youl; Robin H Mortimer; Adedayo A Onitilo; Anthony Russell; Suhail A R Doi
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

3.  Minimally invasive follicular carcinoma: predictors of vascular invasion and impact on patterns of care.

Authors:  Paolo Goffredo; Christa Jillard; Samantha Thomas; Randall P Scheri; Julie Ann Sosa; Sanziana Roman
Journal:  Endocrine       Date:  2015-06-16       Impact factor: 3.633

4.  The total number of tissue blocks per centimetre of tumor significantly correlated with the risk of distant metastasis in patients with minimally invasive follicular thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Tony W H Shek; Arnold L H Wu; Koon Yat Wan
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

6.  A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry.

Authors:  Hop S Tran Cao; Lily E Johnston; David C Chang; Michael Bouvet
Journal:  Surgery       Date:  2012-04-11       Impact factor: 3.982

7.  Validation and Comparison of Nomograms in Predicting Disease-Specific Survival for Papillary Thyroid Carcinoma.

Authors:  Brian Hung-Hin Lang; Carlos K H Wong
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

8.  Risk factors for lateral cervical lymph node involvement in follicular thyroid carcinoma.

Authors:  Haitham Alfalah; Isaac Cranshaw; Thomas Jany; Laurent Arnalsteen; Emmanuelle Leteurtre; Catherine Cardot; François Pattou; Bruno Carnaille
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

Review 9.  Reporting performance of prognostic models in cancer: a review.

Authors:  Susan Mallett; Patrick Royston; Rachel Waters; Susan Dutton; Douglas G Altman
Journal:  BMC Med       Date:  2010-03-30       Impact factor: 8.775

10.  Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa
Journal:  Langenbecks Arch Surg       Date:  2014-02       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.